1. Patick, A. K., Boritzki, T. J., Bloom, L. A.: Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfnavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infectionin vitro. Antimicrob. Agents Chemother. 41 (1996) 2159–2164.
2. Peterson, A. K., Gersten, M., Knowles, M., Chang, Y., Yu, G., Clendeninn, N. J. (Agouron Pharmaceuticals, La Jolla, CA) for the Viracept Cooperative Study Group: Long-term virological and immunological response to treatment with viracept (nelfinavir mesylate) in combination with zidovudine and lamivudine. Program and abstracts of the Sixth European Conference on Clinical Aspects of HIV-Infection, Hamburg, Germany 1997, abstr. no. 210.
3. Nelfinavir prescribing information. Agouron Pharmaceuticals Inc., La Jolla, CA, USA.
4. McDonald, C. K., Kuritzkes, D. R.: Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157 (1997) 951–959.